Johnson & Johnson : JNJ

All Johnson & Johnson Articles

1158 Articles

Jon C. Ogg | Feb 11, 2019 at 7:10 AM EST

The 15 Best Dividend Stocks for Retirees to Own

There are many stocks that are targeted toward mature adults and seniors or that offer classical investing themes for those…

Chris Lange | Jan 24, 2019 at 9:50 AM EST

How the 30 Dow Stocks Are Doing in 2019

24/7 Wall St. has ranked these Dow Stocks on their performance thus far in 2019, as of Wednesday’s closing price.…

Chris Lange | Jan 22, 2019 at 8:30 AM EST

Johnson & Johnson Earnings: When Good Enough Just Isn’t Good Enough

Johnson & Johnson released better-than-expected fourth-quarter financial results before the markets opened on Tuesday.

Trey Thoelcke | Jan 20, 2019 at 9:35 AM EST

7 of This Week’s Most-Anticipated Earnings Reports

Now that the fourth-quarter earnings reporting season has kicked off, more major companies will be sharing their results this week,…

Jon C. Ogg | Dec 18, 2018 at 9:20 AM EST

Boeing and J&J Both Offer New Incentives for Investors After Big Losses

These two members of the thirty Dow Jones industrial average index have been under siege and are now fighting back.

Chris Lange | Dec 14, 2018 at 11:35 AM EST

Johnson & Johnson Under Fire After Claims of Asbestos in Baby Powder

Johnson & Johnson shares dropped on Friday after it came public that the company knew for decades that its baby…

Jon C. Ogg | Nov 27, 2018 at 6:45 AM EST

High Debt Maturities Bring Risk to the Endless Stock Buyback Addiction After 2018

Now that 2018 is nearing an end, it is a serious time for investors to start thinking about expectations in 2019…

Jon C. Ogg | Nov 7, 2018 at 11:00 AM EST

After the Midterm Elections, 10 Defensive Stocks to Buy for 2019

These 10 companies that are likely to have safer business models and will offer some defensive positioning if the economic…

Chris Lange | Oct 16, 2018 at 8:35 AM EDT

Should Johnson & Johnson Be Getting More Out of Q3 Earnings?

Johnson & Johnson reported better-than-expected third-quarter financial results before the markets opened on Thursday.

Chris Lange | Oct 15, 2018 at 10:15 AM EDT

What to Expect When Johnson & Johnson Reports Tuesday

Johnson & Johnson is scheduled to report its third-quarter financial results early Tuesday, and analysts expect solid growth on the…

Chris Lange | Oct 14, 2018 at 7:10 AM EDT

Goldman Sachs, IBM, Amex and More Dow Stocks Reporting This Week

24/7 Wall St. has put together a preview of Johnson & Johnson, Procter & Gamble and the other Dow Jones…

Chris Lange | Oct 4, 2018 at 11:40 AM EDT

Why Arrowhead Pharma’s New Agreement Is a Big Deal

Arrowhead Pharmaceuticals shares stumbled on Thursday after it announced a license and collaboration agreement with Janssen Pharmaceutica, a subsidiary of…

Paul Ausick | Sep 25, 2018 at 4:01 PM EDT

Intel, UnitedHealth Sink the Dow Tuesday

Intel, UnitedHealth, Johnson & Johnson, and 3M Company led the Dow's Tuesday drop.

Paul Ausick | Sep 5, 2018 at 4:01 PM EDT

Visa, Microsoft Hold Back the Dow Wednesday

Trading in the Dow 30 stocks was essentially flat Wednesday with Visa and Microsoft the leading losers while Caterpillar and…

Paul Ausick | Aug 20, 2018 at 4:01 PM EDT

Nike, Johnson & Johnson Lift the Dow Monday

Nike, Johnson & Johnson, Merck, and Home Depot were Monday's leading gainers.

1 … 26 27 28 29 30 … 78

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

The 15 Best Dividend Stocks for Retirees to Own

How the 30 Dow Stocks Are Doing in 2019

Johnson & Johnson Earnings: When Good Enough Just Isn’t Good Enough

7 of This Week’s Most-Anticipated Earnings Reports

Boeing and J&J Both Offer New Incentives for Investors After Big Losses

Johnson & Johnson Under Fire After Claims of Asbestos in Baby Powder

High Debt Maturities Bring Risk to the Endless Stock Buyback Addiction After 2018

After the Midterm Elections, 10 Defensive Stocks to Buy for 2019

Should Johnson & Johnson Be Getting More Out of Q3 Earnings?

What to Expect When Johnson & Johnson Reports Tuesday

Goldman Sachs, IBM, Amex and More Dow Stocks Reporting This Week

Why Arrowhead Pharma’s New Agreement Is a Big Deal

Intel, UnitedHealth Sink the Dow Tuesday

Visa, Microsoft Hold Back the Dow Wednesday

Nike, Johnson & Johnson Lift the Dow Monday

Is President Trump About to Buy a Stake in OpenAI?

Will XRP Drop to $1 if Bitcoin Plunges Below $60K?

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

The Trumps Bought a Vineyard Near This Virginia Town. Can You Afford to Retire There?

Wes Moss Says One Dollar Over the Wrong IRMAA Threshold Can Cost a Retiree Up to $4,000 a Year and Most Advisors Never Mention It

Is President Trump About to Buy a Stake in OpenAI?

Will XRP Drop to $1 if Bitcoin Plunges Below $60K?

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

The 15 Best Dividend Stocks for Retirees to Own

How the 30 Dow Stocks Are Doing in 2019

Johnson & Johnson Earnings: When Good Enough Just Isn’t Good Enough

7 of This Week’s Most-Anticipated Earnings Reports

Boeing and J&J Both Offer New Incentives for Investors After Big Losses

Johnson & Johnson Under Fire After Claims of Asbestos in Baby Powder

High Debt Maturities Bring Risk to the Endless Stock Buyback Addiction After 2018

After the Midterm Elections, 10 Defensive Stocks to Buy for 2019

Should Johnson & Johnson Be Getting More Out of Q3 Earnings?

What to Expect When Johnson & Johnson Reports Tuesday

Goldman Sachs, IBM, Amex and More Dow Stocks Reporting This Week

Why Arrowhead Pharma’s New Agreement Is a Big Deal

Intel, UnitedHealth Sink the Dow Tuesday

Visa, Microsoft Hold Back the Dow Wednesday

Nike, Johnson & Johnson Lift the Dow Monday

Is President Trump About to Buy a Stake in OpenAI?

Will XRP Drop to $1 if Bitcoin Plunges Below $60K?

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Featured Reads

The Trumps Bought a Vineyard Near This Virginia Town. Can You Afford to Retire There?

Wes Moss Says One Dollar Over the Wrong IRMAA Threshold Can Cost a Retiree Up to $4,000 a Year and Most Advisors Never Mention It